Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Jan 30;180(2):321–329. doi: 10.1007/s10549-020-05546-0

Table 2.

Univariate analysis of factors associated with incomplete response to anti-HER2 neoadjuvant chemotherapy

pCR
Covariate Level No N=70 Yes N=83 P-value
Age Median 57 53 0.006
Range 30-86 26-76
Nottingham grade 1-2 29 (43.28) 38 (56.72) 0.595
3 40 (47.62) 44 (52.38)
Nuclear grade 2 23 (42.59) 31 (57.41) 0.568
3 46 (47.42) 51 (52.58)
ER positivity No 28 (35.9) 50 (64.1) 0.013
Yes 42 (56) 33 (44)
PR positivity No 36 (36) 64 (64) <.001
Yes 34 (64.15) 19 (35.85)
HER2 manual IHC score 2 23 (76.67) 7 (23.33) <.001
3 47 (38.21) 76 (61.79)
HER2 DIA connectivity Case # 70 81 <.001
Median 0.75 0.88
Range 0.12-0.98 0.5-0.97
HER2 FISH copy number Case # 56 66 <.001
Median 12.46 19.9
Range 4-35.5 3.6-34.36
HER2 FISH ratio Case # 56 66 <.001
Median 4.19 7.51
Range 0.96-15.5 2.3-22.98

pCR pathologic complete response, ER estrogen receptor, PR progesterone receptor, DIA digital imaging analysis